ISIN | LU0426487442 |
---|---|
No. de valeur | 10173746 |
Bloomberg Global ID | BBG000LZWTW4 |
Nom de fond | PPF ("PMG Partners Funds") - PMG Global Biotech Fund I |
Prestataire de fonds |
PMG Investment Solutions AG
Zug, Schweiz Téléphone: +41 44 215 28 38 E-Mail: pmg@pmg.swiss Web: https://www.pmg.swiss |
Prestataire de fonds | PMG Investment Solutions AG |
Représentant en Suisse |
PMG Investment Solutions AG Zug Téléphone: +41 44 215 28 38 |
Distributeur(s) |
PMG Investment Solutions AG Zug Téléphone: +41 44 215 28 38 |
Classe d'actifs | Fonds en actions |
EFC Catégorie | |
Catégorie de parts | Accumulation |
Pays d'origine | Luxembourg |
Conditions d'émission de parts | Commission d'émission en faveur de la direction du fonds et/ou du distributeur (peut être différente pour le même fonds en fonction de la filière de distribution) |
Conditions de rachat de parts | Pas de commission de rachat et/ou de taxes en faveur du fonds (le rachat a lieu à la valeur d'inventaire) |
Stratégie d'investissement *** | The objective of the investment policy of the Subfund is to achieve the highest possible long-term capital growth in US dollars by taking advantage of the opportunities offered by biotech and pharmaceutical shares on the global stock markets. This involves investing in listed shares of companies that specialise in the identification, development and production of innovative chemical products for the healthcare sector. To achieve the investment objectives, the subfund will primarily invest in equities and, in part, in futures and exchange-traded options. The country-specific focus of the Fund is on the United States, Europe and the Asia region. This focus also includes investments in emerging markets in Europe and Asia. Investments are made in securities irrespective of their market capitalisation (small cap, mid cap, large cap). Up to 10% of the assets of the subfund may also be invested in China Connect Securities via the Stock Connect Programme. |
Particularités |
Prix actuel * | 90.39 USD | 30.10.2024 |
---|---|---|
Prix précédent * | 90.28 USD | 29.10.2024 |
Max 52 semaines * | 95.45 USD | 21.08.2024 |
Min 52 semaines * | 75.98 USD | 13.11.2023 |
NAV * | 90.39 USD | 30.10.2024 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Prix minimal indicatif | ||
Actifs du fonds *** | 17'164'238 | |
Actifs de la classe *** | 12'350'811 | |
Trading Information SIX |
YTD Performance | +3.29% |
29.12.2023 - 30.10.2024
29.12.2023 30.10.2024 |
---|---|---|
YTD Performance (en CHF) | +6.34% |
29.12.2023 - 30.10.2024
29.12.2023 30.10.2024 |
1 mois | -1.64% |
30.09.2024 - 30.10.2024
30.09.2024 30.10.2024 |
3 mois | -3.92% |
30.07.2024 - 30.10.2024
30.07.2024 30.10.2024 |
6 mois | +12.44% |
30.04.2024 - 30.10.2024
30.04.2024 30.10.2024 |
1 an | +21.10% |
30.10.2023 - 30.10.2024
30.10.2023 30.10.2024 |
2 ans | -2.86% |
31.10.2022 - 30.10.2024
31.10.2022 30.10.2024 |
3 ans | -33.91% |
02.11.2021 - 30.10.2024
02.11.2021 30.10.2024 |
5 ans | -8.47% |
30.10.2019 - 30.10.2024
30.10.2019 30.10.2024 |
Quota de participation de capital en % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Part de la fortune du fonds en % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quota d'immobilier en % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
SIGA Technologies Inc | 6.71% | |
---|---|---|
Regeneron Pharmaceuticals Inc | 5.23% | |
Amgen Inc | 5.06% | |
Moderna Inc | 4.84% | |
Vertex Pharmaceuticals Inc | 3.65% | |
Biogen Inc | 3.60% | |
Illumina Inc | 3.60% | |
Chimerix Inc | 3.51% | |
BioNTech SE ADR | 3.31% | |
Seagen Inc Ordinary Shares | 2.86% | |
Dernière mise à jour des données | 31.08.2022 |
TER | 2.12% |
---|---|
Date TER | 30.06.2024 |
Performance Fee *** | 20.00% |
PTR | |
Max. Management Fee *** | 1.20% |
Ongoing Charges *** | 1.70% |
SRRI ***
|
|
Date SRRI *** | 31.10.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |